| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/08/2023 | — | Cantor Fitzgerald | Initiates Coverage On | → Neutral | |
| 07/26/2023 | 394.62% | HC Wainwright & Co. | $25 → $23 | Maintains | Buy |
| 07/14/2023 | 394.62% | Truist Securities | $23 → $23 | Reiterates | Buy → Buy |
| 07/11/2023 | 394.62% | Truist Securities | → $23 | Initiates Coverage On | → Buy |
| 05/10/2023 | 437.63% | HC Wainwright & Co. | $26 → $25 | Maintains | Buy |
| 03/14/2023 | 459.14% | HC Wainwright & Co. | $27 → $26 | Maintains | Buy |
| 03/10/2023 | 308.6% | RBC Capital | → $19 | Reiterates | → Outperform |
| 03/10/2023 | 588.17% | Oppenheimer | $36 → $32 | Maintains | Outperform |
| 08/29/2022 | 717.2% | Citigroup | $39 → $38 | Maintains | Buy |
| 08/18/2022 | 480.65% | HC Wainwright & Co. | $28 → $27 | Maintains | Buy |
| 08/10/2022 | 308.6% | RBC Capital | $22 → $19 | Maintains | Outperform |
| 05/13/2022 | 738.71% | Citigroup | $29 → $39 | Maintains | Buy |
| 05/12/2022 | 631.18% | SVB Leerink | $30 → $34 | Maintains | Outperform |
| 05/10/2022 | 545.16% | SVB Leerink | $29 → $30 | Maintains | Outperform |
| 03/22/2022 | 523.66% | SVB Leerink | $32 → $29 | Maintains | Outperform |
| 02/18/2022 | 373.12% | RBC Capital | → $22 | Initiates Coverage On | → Outperform |
| 02/14/2022 | 308.6% | Brookline Capital | → $19 | Initiates Coverage On | → Buy |
| 12/01/2021 | 674.19% | Oppenheimer | → $36 | Initiates Coverage On | → Outperform |
| 11/30/2021 | 502.15% | HC Wainwright & Co. | → $28 | Initiates Coverage On | → Buy |
| 11/15/2021 | 480.65% | Citigroup | → $27 | Upgrades | Neutral → Buy |
| 08/17/2021 | 480.65% | Citigroup | → $27 | Initiates Coverage On | → Neutral |
| 08/17/2021 | 545.16% | B of A Securities | → $30 | Initiates Coverage On | → Buy |
| 08/17/2021 | 588.17% | SVB Leerink | → $32 | Initiates Coverage On | → Outperform |
What is the target price for Caribou Biosciences (CRBU)?
The latest price target for Caribou Biosciences (NASDAQ: CRBU) was reported by Cantor Fitzgerald on November 8, 2023. The analyst firm set a price target for $0.00 expecting CRBU to fall to within 12 months (a possible -100.00% downside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Caribou Biosciences (CRBU)?
The latest analyst rating for Caribou Biosciences (NASDAQ: CRBU) was provided by Cantor Fitzgerald, and Caribou Biosciences initiated their neutral rating.
When is the next analyst rating going to be posted or updated for Caribou Biosciences (CRBU)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Caribou Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Caribou Biosciences was filed on November 8, 2023 so you should expect the next rating to be made available sometime around November 8, 2024.
Is the Analyst Rating Caribou Biosciences (CRBU) correct?
While ratings are subjective and will change, the latest Caribou Biosciences (CRBU) rating was a initiated with a price target of $0.00 to $0.00. The current price Caribou Biosciences (CRBU) is trading at is $4.65, which is out of the analyst's predicted range.